<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151059</url>
  </required_header>
  <id_info>
    <org_study_id>V71_19S</org_study_id>
    <nct_id>NCT01151059</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects</brief_title>
  <official_title>A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, When Administered to Non-elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will evaluate the safety and immunogenicity in healthy people (non-elderly
      adult and elderly subjects) after one intramuscular (IM) dose of trivalent subunit
      inactivated flu vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the antibody response to each influenza vaccine antigen at 21 days post-immunization in non-elderly adult and elderly subjects</measure>
    <time_frame>22 days, including the follow-up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of a single IM injection of trivalent subunit inactivated FLU vaccine in non-elderly adult and elderly subjects</measure>
    <time_frame>22 days, including the follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent subunit inactivated flu vaccine, Formulation 2010-2011</intervention_name>
    <description>This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females volunteers of 18 years of age or older, mentally competent, willing
             and able to give written informed consent prior to study entry

          -  Individuals able to complain with all the study requirements

          -  Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Exclusion Criteria:

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the subject's ability to
             participate in the study

          -  Individuals with any serious chronic or acute disease (in the judgment of the
             investigator), including but not limited to: cancer, advanced congestive heart
             failure, chronic obstructive pulmonary disease (COPD), autoimmune diseases, acute or
             progressive hepatic and renal disease, severe neurological or psychiatric disorder and
             severe asthma

          -  Individuals with history of any anaphylactic reaction and/or serious allergic reaction
             following a vaccination, a proven hypersensitivity to any component of the study
             vaccine (e.g. to eggs/eggs product as well as ovalbumin, chicken protein, chicken
             feathers, influenza viral protein, kanamycin and neomycin sulphate)

          -  Individuals with known or suspected impairment/alteration of immune function
             resulting, for example, from: receipt of immunosuppressive therapy within the past 60
             days and for the full length of the study, receipt of immunostimulants, receipt of
             parenteral immunoglobulin preparation, blood products and/or plasma derivates within
             the past 3 months and for the full length of the study and suspected or known human
             immunodeficiency virus (HIV) infection or HIV-related disease

          -  Individuals with known or suspected history of drug or alcohol abuse

          -  Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing
             potential do not plan to use acceptable birth control measures for the whole duration
             of the study

          -  Individuals with history or any illness that, in the opinion of the investigator,
             might interfere with the results of the study or pose additional risk to the subjects
             due to participation in the study

          -  Individuals within the past 6 months, they have had any seasonal or pandemic
             laboratory confirmed influenza disease and received any seasonal or pandemic influenza
             vaccine

          -  Individuals with any acute or chronic infections requiring systemic antibiotic
             treatment or antiviral therapy within the last 7 days

          -  Individuals that have experienced fever (i.e., axillary temperature ≥ 38°C) within the
             last 3 days of intended study vaccination

          -  Individuals participating in any clinical trial with another investigational product 4
             weeks prior to first study visit or intent to participate in another clinical study at
             any time during the conduct of this study

          -  Individuals who received any other vaccines within 4 weeks prior to enrollment in this
             study or who are planning to receive any vaccine within 4 weeks from the study
             vaccines

          -  Individuals who have ever received blood/blood products and/or plasma derivatives or
             any parenteral immunoglobulin preparation in the past 12 weeks and for the full length
             of the study

          -  Individuals who are part of study personnel or close family members conducting this
             study

          -  Individuals with a bleeding diathesis or conditions associated with prolonged bleeding
             time that in the investigator's opinion would interfere with the safety of the subject

          -  BMI &gt; 35 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via dei Vestini</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale - Sezione di Igiene e Medicina Preventiva, Via Fossato di Mortara, 64/b</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze della Salute Università di Genova Via Pastore, 1</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Satellite. ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37</name>
      <address>
        <city>Lanciano</city>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine and Immunotherapy Research Center Department of Infectious and Tropical Diseases San Raffaele Scientific Institute Via Stamira d'Ancona, 20</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seasonal influenza</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

